HQY vs LMAT: fair value comparison
HealthEquity, Inc. and LeMaitre Vascular, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, HQY currently sits closer to the top of our discount ranking.
| HQY | LMAT | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $97.00 | $81.08 |
| 12-month range | $77.93–$104.36 | $79.54–$111.42 |
| Sector rank | #20 of 113 Healthcare | #23 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: HQY fair value analysis · LMAT fair value analysis